Advertisement

Neonatology pp 433-440 | Cite as

Surfactant Metabolism in Neonatal Lung Diseases

  • Virgilio P. Carnielli
  • Paola E. Cogo

Abstract

Pulmonary surfactant reduces surface tension in the lungs to impressive low values. When secreted by the type II cells into the thin liquid layer that lines the alveolar air spaces, vesicles of pulmonary surfactant absorb readily to the air water interface and form an interfacial film. The surfactant unique tensioactive properties were originally explained by its unique phospholipid composition, which is strikingly comparable across species [1]. Of the surfactant lipids, 80–90% are phospholipids, of which phosphatidylcholine (PC) is quantitatively the most important, accounting for 70–80% of the total. Other lipids include phosphatidylglycerol (PG), phosphatidylethanolamine, phosphatidylinositol, phosphatidylserine, sphingomyelin, cholesterol, triacylglycerols, and free fatty acids. Approximately 60% of the PC contains two saturated fatty acids (DSPC) of which dipalmitoyl (16:0/16:0; DPPC) is the most abundant. DPPC and PG are key phospholipids that permit normal breathing by reducing surface tension to near zero at the end of the respiratory cycle.

Keywords

Respiratory Distress Syndrome Congenital Diaphragmatic Hernia Extubation Failure Meconium Aspiration Syndrome Exogenous Surfactant 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. 1.
    Hunt AN, Kelly FJ, Postle AD (1991) Developmental variation in whole human lung phosphatidylcholine molecular species: a comparison with guinea pig and rat. Early Hum Dev 25:157–171PubMedCrossRefGoogle Scholar
  2. 2.
    Haagsman HP, Diemel RV (2001) Surfactant-associated proteins: functions and structural variation. Comp Biochem Physiol A Mol Integr Physiol 129:91–108PubMedCrossRefGoogle Scholar
  3. 3.
    Korfhagen TR, Bruno MD, Ross GF et al (1996) Altered surfactant function and structure in SP-A gene targeted mice. Proc Natl Acad Sci USA 93:9594–9599PubMedCrossRefGoogle Scholar
  4. 4.
    Crouch EC (1998) Collectins and pulmonary host defense. Am J Respir Cell Mol Biol 19:177–201PubMedGoogle Scholar
  5. 5.
    Botas C, Poulain F, Akiyama J et al (1998) Altered surfactant homeostasis and alveolar type II cell morphology in mice lacking surfactant protein D. Proc Natl Acad Sci USA 95:11869–11874PubMedCrossRefGoogle Scholar
  6. 6.
    Nogee LM, de Mello DE, Dehner LP, Colten HR (1993) Brief report: deficiency of pulmonary surfactant protein B in congenital alveolar proteinosis. N Engl J Med 328:406–410PubMedCrossRefGoogle Scholar
  7. 7.
    deMello DE, Heyman S, Phelps DS et al (1994) Ultrastructure of lung in surfactant protein B deficiency. Am J Respir Cell Mol Biol 11:230–239PubMedGoogle Scholar
  8. 8.
    Glasser SW, Burhans MS, Korfhagen TR et al (2001) Altered stability of pulmonary surfactant in SP-C-deficient mice. Proc Natl Acad Sci USA 98:6366–6371PubMedCrossRefGoogle Scholar
  9. 9.
    Rebello CM, Jobe AH, Eisele JW, Ikegami M (1996) Alveolar and tissue surfactant pool sizes in humans. Am J Respir Crit Care Med 154:625–628PubMedGoogle Scholar
  10. 10.
    Batenburg JJ (1992) Surfactant phospholipids: synthesis and storage. Am J Physiol 262(4 Part 1):L367–L385PubMedGoogle Scholar
  11. 11.
    Jacobs H, Jobe A, Ikegami M, Conaway D (1983) The significance of reutilization of surfactant phosphatidylcholine. J Biol Chem 258:4156–4165Google Scholar
  12. 12.
    Wright JR, Dobbs LG (1991) Regulation of pulmonary surfactant secretion and clearance. Annu Rev Physiol 53:395–414PubMedCrossRefGoogle Scholar
  13. 13.
    Martini WZ, Chinkes DL, Barrow RE et al (1999) Lung surfactant kinetics in conscious pigs. Am J Physiol 277:E187–E195PubMedGoogle Scholar
  14. 14.
    Jacobs HC, Ikegami M, Jobe AH et al (1985) Reutilization of surfactant phosphatidylcholine in adult rabbits. Biochim Biophys Acta 837:77–84PubMedGoogle Scholar
  15. 15.
    Jobe A, Ikegami M, Sarton-Miller I, Barajas L (1980) Surfactant metabolism of newborn lamb lungs in vivo. J Appl Physiol 49:1091–1098PubMedGoogle Scholar
  16. 16.
    Jobe A (1988) Metabolism of endogenous surfactant and exogenous surfactant for replacement therapy. Semin Perinatol 12:231–239PubMedGoogle Scholar
  17. 17.
    Jobe A, Ikegami M, Glatz T et al (1983) Saturated phosphatidylcholine secretion and the effect of natural surfactant on premature and term lambs ventilated for 2 days. Exp Lung Res 4:259–267PubMedCrossRefGoogle Scholar
  18. 18.
    Bunt JE, Zimmermann LJ, Wattimena JL et al (1998) Endogenous surfactant turnover in preterm infants measured with stable isotopes. Am J Respir Crit Care Med 157(3 Part 1):810–814PubMedGoogle Scholar
  19. 19.
    Merchak A, Janssen DJ, Bohlin K et al (2002) Endogenous pulmonary surfactant metabolism is not affected by mode of ventilation in premature infants with respiratory distress syndrome. J Pediatr 140:693–698PubMedCrossRefGoogle Scholar
  20. 20.
    Cavicchioli P, Zimmermann LJ, Cogo PE et al (2001) Endogenous surfactant turnover in preterm infants with respiratory distress syndrome studied with stable isotope lipids. Am J Respir Crit Care Med 163:55–60PubMedGoogle Scholar
  21. 21.
    Bohlin K, Merchak A, Spence K et al (2003) Endogenous surfactant metabolism in newborn infants with and without respiratory failure. Pediatr Res 54:185–191PubMedCrossRefGoogle Scholar
  22. 22.
    Cogo PE, Zimmermann LJ, Rosso F et al (2002) Surfactant synthesis and kinetics in infants with congenital diaphragmatic hernia. Am J Respir Crit Care Med 166:154–158PubMedCrossRefGoogle Scholar
  23. 23.
    Janssen DJMT (2003) Surfactant phosphatidylcholine metabolism in severe neonatal lung disease studied with stable isotopes. PhD Thesis. Erasmus Universiteit, RotterdamGoogle Scholar
  24. 24.
    Glatz T, Ikegami M, Jobe A (1982) Metabolism of exogenously administered natural surfactant in the newborn lamb. Pediatr Res 16:711–715PubMedCrossRefGoogle Scholar
  25. 25.
    Seidner SR, Jobe AH, Coalson JJ, Ikegami M (1998) Abnormal surfactant metabolism and function in preterm ventilated baboons. Am J Respir Crit Care Med 158:1982–1989PubMedGoogle Scholar
  26. 26.
    Bunt JE, Carnielli VP, Janssen DJ et al (2000) Treatment with exogenous surfactant stimulates endogenous surfactant synthesis in premature infants with respiratory distress syndrome. Crit Care Med 28:3383–3388PubMedCrossRefGoogle Scholar
  27. 27.
    Cogo PE, Carnielli VP, Bunt JE et al (1999) Endogenous surfactant metabolism in critically ill infants measured with stable isotopes labeled fatty acids. Pediatr Res 45:242–246PubMedCrossRefGoogle Scholar
  28. 28.
    Oulton M, Fraser M, Dolphin M et al (1986) Quantification of surfactant pool sizes in rabbit lung during perinatal development. J Lipid Res 27:602–612PubMedGoogle Scholar
  29. 29.
    Gluck L, Kulovich MV, Borer RC Jr, Keidel WN (1974) The interpretation and significance of the lecithin-sphingomyelin ratio in amniotic fluid. Am J Obstet Gynecol 120:142–155PubMedGoogle Scholar
  30. 30.
    Faridy EE, Thliveris JA (1987) Rate of secretion of lung surfactant before and after birth. Respir Physiol 68:269–277PubMedCrossRefGoogle Scholar
  31. 31.
    Verlato G, Cogo PE, Balzani M et al (2008) Surfactant status in preterm neonates recovering from respiratory distress syndrome. Pediatrics 122:102–108PubMedCrossRefGoogle Scholar
  32. 32.
    Hallman M, Merritt TA, Pohjavuori M, Gluck L (1986) Effect of surfactant substitution on lung effluent phospholipids in respiratory distress syndrome: evaluation of surfactant phospholipid turnover, pool size, and the relationship to severity of respiratory failure. Pediatr Res 20:1228–1235PubMedCrossRefGoogle Scholar
  33. 33.
    Griese M, Dietrich P, Reinhardt D (1995) Pharmacokinetics of bovine surfactant in neonatal respiratory distress syndrome. Am J Respir Crit Care Med 152:1050–1054PubMedGoogle Scholar
  34. 34.
    Torresin M, Zimmermann LJ, Cogo PE et al (2000) Exogenous surfactant kinetics in infant respiratory distress syndrome: A novel method with stable isotopes. Am J Respir Crit Care Med 161:1584–1589PubMedGoogle Scholar
  35. 35.
    Cogo PE, Zimmermann LJ, Meneghini L et al (2003) Pulmonary surfactant disaturated-phosphatidylcholine (DSPC) turnover and pool size in newborn infants with congenital diaphragmatic hernia (CDH). Pediatr Res 54:653–658PubMedCrossRefGoogle Scholar
  36. 36.
    Oetomo SB, Lewis J, Ikegami M, Jobe AH (1990) Surfactant treatments alter endogenous surfactant metabolism in rabbit lungs. J Appl Physiol 68:1590–1596PubMedGoogle Scholar
  37. 37.
    Ikegami M, Jobe A, Yamada T et al (1989) Surfactant metabolism in surfactant-treated preterm ventilated lambs. J Appl Physiol 67:429–437PubMedGoogle Scholar
  38. 38.
    Oguchi K, Ikegami M, Jacobs H, Jobe A (1985) Clearance of large amounts of natural surfactants and liposomes of dipalmitoylphosphatidylcholine from the lungs of rabbits. Exp Lung Res 9:221–235PubMedCrossRefGoogle Scholar
  39. 39.
    Cogo PE, Facco M, Simonato M et al (2011) Pharmacokinetics and clinical predictors of surfactant redosing in respiratory distress syndrome. Intensive Care Med 37:510–517PubMedCrossRefGoogle Scholar
  40. 40.
    Cogo PE, Facco M, Simonato M et al (2009) Dosing of porcine surfactant: effect on kinetics and gas exchange in respiratory distress syndrome. Pediatrics 124:e950–e957PubMedCrossRefGoogle Scholar
  41. 41.
    Spragg RG, Li J (2000) Effect of phosphocholine cytidylyltransferase overexpression on phosphatidylcholine synthesis in alveolar type II cells and related cell lines. Am J Respir Cell Mol Biol 22:116–124PubMedGoogle Scholar
  42. 42.
    Rooney SA, Gobran LI, Marino PA et al (1979) Effects of betamethasone on phospholipid content, composition and biosynthesis in the fetal rabbit lung. Biochim Biophys Acta 572:64–76PubMedGoogle Scholar
  43. 43.
    Ballard PL (1989) Hormonal regulation of pulmonary surfactant Endocr Rev 10:165–181PubMedCrossRefGoogle Scholar
  44. 44.
    Pope TS, Rooney SA (1987) Effects of glucocorticoid and thyroid hormones on regulatory enzymes of fatty acid synthesis and glycogen metabolism in developing fetal rat lung. Biochim Biophys Acta 918:141–148PubMedGoogle Scholar
  45. 45.
    Post M, Barsoumian A, Smith BT (1986) The cellular mechanism of glucocorticoid acceleration of fetal lung maturation Fibroblastpneumonocyte factor stimulates choline-phosphate cytidylyltransferase activity. J Biol Chem 261:179–184Google Scholar
  46. 46.
    Gonzales LW, Ertsey R, Ballard PL et al (1990) Glucocorticoid stimulation of fatty acid synthesis in explants of human fetal lung. Biochim Biophys Acta 1042:1–12PubMedGoogle Scholar
  47. 47.
    Tan RC, Ikegami M, Jobe AH et al (1999) Developmental and glucocorticoid regulation of surfactant protein mRNAs in preterm lambs. Am J Physiol 277(6 Part 1):L1142–L1148PubMedGoogle Scholar
  48. 48.
    Kessler DL, Truog WE, Murphy JH et al (1982) Experimental hyaline membrane disease in the premature monkey: effects of antenatal dexamethasone. Am Rev Respir Dis 126:62–69PubMedGoogle Scholar
  49. 49.
    Bunt JE, Carnielli VP, Seidner SR et al (1999) Metabolism of Endogenous Surfactant in Premature Baboons and Effect of Prenatal Corticosteroids. Am J Respir Crit Care Med 160:1481–1485PubMedGoogle Scholar
  50. 50.
    Bunt JE, Carnielli VP, Darcos Wattimena JL et al (2000) The effect in premature infants of prenatal corticosteroids on endogenous surfactant synthesis as measured with stable isotopes. Am J Respir Crit Care Med 162(3 Part 1):844–849PubMedGoogle Scholar
  51. 51.
    Ikegami M, Polk D, Jobe A (1996) Minimum interval from fetal betamethasone treatment to postnatal lung responses in preterm lambs. Am J Obstet Gynecol 174:1408–1413PubMedCrossRefGoogle Scholar
  52. 52.
    Beck JC, Mitzner W, Johnson JW et al (1981) Betamethasone and the rhesus fetus: effect on lung morphometry and connective tissue. Pediatr Res 15:235–240PubMedCrossRefGoogle Scholar
  53. 53.
    Walther FJ, Jobe AH, Ikegami M (1998) Repetitive prenatal glucocorticoid therapy reduces oxidative stress in the lungs of preterm lambs. J Appl Physiol 85:273–278PubMedGoogle Scholar
  54. 54.
    Walther FJ, Ikegami M, Warburton D, Polk DH (1991) Corticosteroids, thyrotropin-releasing hormone, and antioxidant enzymes in preterm lamb lungs. Pediatr Res 30:518–521PubMedCrossRefGoogle Scholar
  55. 55.
    Ikegami M, Berry D, elKady T et al (1987) Corticosteroids and surfactant change lung function and protein leaks in the lungs of ventilated premature rabbits. J Clin Invest 79:1371–1378PubMedCrossRefGoogle Scholar
  56. 56.
    Ballard RA, Ballard PL (1996) Antenatal hormone therapy for improving the outcome of the preterm infant. J Perinatol 16:390–396PubMedGoogle Scholar
  57. 57.
    Pinkerton KE, Willet KE, Peake JL et al (1997) Prenatal glucocorticoid and T4 effects on lung morphology in preterm lambs. Am J Respir Crit Care Med 156(2 Part 1):624–630PubMedGoogle Scholar
  58. 58.
    Merrill JD, Ballard PL, Hibbs AM et al (2006) Booster surfactant therapy beyond the first week of life in ventilated extremely low gestational age neonates. J Investig Med 54:S108Google Scholar
  59. 59.
    Herting E, Gefeller O, Land M et al (2000) Surfactant treatment of neonates with respiratory failure and group B streptococcal infection. Members of the Collaborative European Multicenter Study Group. Pediatrics 106:957–964, discussion 1135PubMedCrossRefGoogle Scholar
  60. 60.
    Herting E, Möller O, Schiffmann JH, Robertson B (2002) Surfactant improves oxygenation in infants and children with pneumonia and acute respiratory distress syndrome. Acta Paediatr 91:1174–1178PubMedCrossRefGoogle Scholar
  61. 61.
    Finer NN (2004) Surfactant use for neonatal lung injury: beyond respiratory distress syndrome. Paediatr Respir Rev 5(Suppl A):S289–S297PubMedCrossRefGoogle Scholar
  62. 62.
    Fetter WP, Baerts W, Bos AP, van Lingen RA (1995) Surfactant replacement therapy in neonates with respiratory failure due to bacterial sepsis. Acta Paediatr 84:14–16PubMedCrossRefGoogle Scholar
  63. 63.
    Rivera S, Gaugler C, Langlet C et al (2004) [Secondary surfactant deficiencies in extremely low birth weight premature infants.] Arch Pediatr 11:1346–1350PubMedGoogle Scholar
  64. 64.
    Escande B, Kuhn P, Rivera S, Messer J (2004) [Secondary surfactant deficiencies.] Arch Pediatr 11:1351–1359PubMedCrossRefGoogle Scholar
  65. 65.
    Auten RL, Notter RH, Kendig JW et al (1991) Surfactant treatment of full-term newborns with respiratory failure. Pediatrics 87:101–107PubMedGoogle Scholar
  66. 66.
    Chinese Collaborative Study Group for Neonatal Respiratory Distress. (2005) Treatment of severe meconium aspiration syndrome with porcine surfactant: a multicentre, randomized, controlled trial. Acta Paediatr 94:896–902CrossRefGoogle Scholar
  67. 67.
    Hintz SR, Suttner DM, Sheehan AM et al (2000) Decreased use of neonatal extracorporeal membrane oxygenation (ECMO): how new treatment modalities have affected ECMO utilization. Pediatrics 106:1339–1343PubMedCrossRefGoogle Scholar
  68. 68.
    Verlato G, Cogo PE, Pesavento R et al (2003) Surfactant kinetics in newborn infants with pneumonia and respiratory distress syndrome. Ital J Pediatr 29:414–419Google Scholar
  69. 69.
    Moses D, Holm BA, Spitale P et al (1991) Inhibition of pulmonary surfactant function by meconium. Am J Obstet Gynecol 164:477–481PubMedGoogle Scholar
  70. 70.
    Sun B, Curstedt T, Robertson B (1993) Surfactant inhibition in experimental meconium aspiration. Acta Paediatr 82:182–189PubMedCrossRefGoogle Scholar
  71. 71.
    Bae CW, Takahashi A, Chida S, Sasaki M (1998) Morphology and function of pulmonary surfactant inhibited by meconium. Pediatr Res 44:187–191PubMedCrossRefGoogle Scholar
  72. 72.
    Cleary GM, Antunes MJ, Ciesielka DA et al (1997) Exudative lung injury is associated with decreased levels of surfactant proteins in a rat model of meconium aspiration. Pediatrics 100:998–1003PubMedCrossRefGoogle Scholar
  73. 73.
    Dargaville PA, South M, McDougall PN (2001) Surfactant and surfactant inhibitors in meconium aspiration syndrome. J Pediatr 138:113–115PubMedCrossRefGoogle Scholar
  74. 74.
    Lotze A, Whitsett JA, Kammerman LA et al (1990) Surfactant protein A concentrations in tracheal aspirate fluid from infants requiring extracorporeal membrane oxygenation. J Pediatr 116:435–440PubMedCrossRefGoogle Scholar
  75. 75.
    Lotze A, Knight GR, Martin GR et al (1993) Improved pulmonary outcome after exogenous surfactant therapy for respiratory failure in term infants requiring extracorporeal membrane oxygenation. J Pediatr 122:261–268PubMedCrossRefGoogle Scholar
  76. 76.
    Higgins ST, Wu AM, Sen N et al (1996) Meconium increases surfactant secretion in isolated rat alveolar type II cells. Pediatr Res 39:443–447PubMedCrossRefGoogle Scholar
  77. 77.
    Janssen DJ, Tibboel D, Carnielli VP et al (2003) Surfactant phosphatidylcholine pool size in human neonates with congenital diaphragmatic hernia requiring ECMO. J Pediatr 142:247–252PubMedCrossRefGoogle Scholar
  78. 78.
    Sun B, Curstedt T, Robertson B (1996) Exogenous surfactant improves ventilation efficiency and alveolar expansion in rats with meconium aspiration. Am J Respir Crit Care Med 154(3 Part 1):764–770PubMedGoogle Scholar
  79. 79.
    Halliday HL, Speer CP, Robertson B (1996) Treatment of severe meconium aspiration syndrome with porcine surfactant. Collaborative Surfactant Study Group Eur J Pediatr 155:1047–1051Google Scholar
  80. 80.
    Findlay RD, Taeusch HW, Walther FJ (1996) Surfactant replacement therapy for meconium aspiration syndrome. Pediatrics 97:48–52PubMedGoogle Scholar
  81. 81.
    Lotze A, Mitchell BR, Bulas DI et al (1998) Multicenter study of surfactant (beractant) use in the treatment of term infants with severe respiratory failure. Survanta in Term Infants Study Group. J Pediatr 132:40–47PubMedCrossRefGoogle Scholar
  82. 82.
    Cochrane CG, Revak SD, Merritt TA et al (1998) Bronchoalveolar lavage with KL4-surfactant in models of meconium aspiration syndrome. Pediatr Res 44:705–715PubMedCrossRefGoogle Scholar
  83. 83.
    Möller JC, Kohl M, Reiss II et al (1999) Saline lavage with substitution of bovine surfactant in term neonates with meconium aspiration syndrome (MAS) transferred for extracorporeal membrane oxygenation (ECMO): a pilot study. Crit Care 3:19–22PubMedCrossRefGoogle Scholar
  84. 84.
    Wiswell TE, Knight GR, Finer NN et al (2002) A multicenter, randomized, controlled trial comparing Surfaxin (Lucinactant) lavage with standard care for treatment of meconium aspiration syndrome. Pediatrics 109:1081–1087PubMedCrossRefGoogle Scholar
  85. 85.
    Glick PL, Stannard VA, Leach C et al (1992) Pathophysiology of congenital diaphragmatic hernia II: the fetal lamb CDH model is surfactant deficient. J Pediatr Surg 27:382–387PubMedCrossRefGoogle Scholar
  86. 86.
    Wilcox DT, Glick PL, Karamanoukian HL et al (1995) Pathophysiology of congenital diaphragmatic hernia XII: Amniotic fluid lecithin/sphingomyelin ratio and phosphatidylglycerol concentrations do not predict surfactant status in congenital diaphragmatic hernia. J Pediatr Surg 30:410–412PubMedCrossRefGoogle Scholar
  87. 87.
    Sullivan KM, Hawgood S, Flake AW et al (1994) Amniotic fluid phospholipid analysis in the fetus with congenital diaphragmatic hernia. J Pediatr Surg 29:1020–1023PubMedCrossRefGoogle Scholar
  88. 88.
    Moya FR, Thomas VL, Romaguera J et al (1995) Fetal lung maturation in congenital diaphragmatic hernia. Am J Obstet Gynecol 173:1401–1405PubMedCrossRefGoogle Scholar
  89. 89.
    Minowa H, Takahashi Y, Kawaguchi C et al (2000) Expression of intrapulmonary surfactant apoprotein-A in autopsied lungs: comparative study of cases with or without pulmonary hypoplasia. Pediatr Res 48:674–678PubMedCrossRefGoogle Scholar
  90. 90.
    IJsselstijn H, Zimmermann LJ, Bunt JE et al (1998) Prospective evaluation of surfactant composition in bronchoalveolar lavage fluid of infants with congenital diaphragmatic hernia and of age-matched controls. Crit Care Med 26:573–580PubMedCrossRefGoogle Scholar
  91. 91.
    Cogo PE, Zimmermann LJ, Verlato G et al (2004) A Dual Stable Isotope Tracer Method for the Measurement of Surfactant Disaturated-Phosphatidylcholine Net Synthesis in Infants with Congenital Diaphragmatic Hernia. Pediatr Res 56:184–190PubMedCrossRefGoogle Scholar
  92. 92.
    Bos AP, Tibboel D, Hazebroek FW et al (1991) Surfactant replacement therapy in high-risk congenital diaphragmatic hernia. Lancet 338:1279PubMedCrossRefGoogle Scholar
  93. 93.
    Glick PL, Leach CL, Besner GE et al (1992) Pathophysiology of congenital diaphragmatic hernia III: Exogenous surfactant therapy for the high-risk neonate with CDH. J Pediatr Surg 27:866–869PubMedCrossRefGoogle Scholar
  94. 94.
    Lotze A, Knight GR, Anderson KD et al (1994) Surfactant (beractant) therapy for infants with congenital diaphragmatic hernia on ECMO: evidence of persistent surfactant deficiency. J Pediatr Surg 29:407–412PubMedCrossRefGoogle Scholar
  95. 95.
    Van Meurs K (2004) Is surfactant therapy beneficial in the treatment of the term newborn infant with congenital diaphragmatic hernia? J Pediatr 145:312–316Google Scholar
  96. 96.
    Lally KP, Lally PA, Langham MR et al (2004) Surfactant does not improve survival rate in preterm infants with congenital diaphragmatic hernia. J Pediatr Surg 39:829–833PubMedCrossRefGoogle Scholar
  97. 97.
    Sakurai Y, Azarow K, Cutz E et al (1999) Pulmonary barotrauma in congenital diaphragmatic hernia: a clinicopathological correlation. J Pediatr Surg 34:1813–1817PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Italia 2012

Authors and Affiliations

  • Virgilio P. Carnielli
    • 1
    • 2
  • Paola E. Cogo
  1. 1.Division of NeonatologySalesi HospitalAnconaItaly
  2. 2.Polytechnic University of MarcheAnconaItaly

Personalised recommendations